Generational shift of the treatment of classical Hodgkin lymphoma
Authors:
A. Sýkorová 1; H. Mociková 2; V. Procházka 3
Authors‘ workplace:
IV. interní hematologická klinika LF UK a FN Hradec Králové
1; Hematologická klinika 3. LF UK a FNKV, Praha
2; Hemato-onkologická klinika LF UP a FN Olomouc
3
Published in:
Transfuze Hematol. dnes,31, 2025, No. Ahead of Print, p. 1-16.
Category:
Review/Educational Papers
doi:
https://doi.org/10.48095/cctahd202521
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2025 Issue Ahead of Print
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
- Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
Most read in this issue
- Recommendations for chronic lymphocytic leukaemia dia gnosis and therapy
- Antithrombotic prophylaxis for women in pregnancy, childbirth and the postpartum period
- Is long-term administration of interferons in polycythaemia vera associated with risks?
- MYC gene and its abnormalities with a focus on aggressive B-cell lymphomas